ACC to collect COVID-19 data through NCDR Chest Pain-MI and CathPCI registries

ACC to collect COVID-19 data through NCDR Chest Pain-MI and CathPCI registries

What happens when COVID-19 and cardiovascular diseases mix? In was clear early in the onset of the global pandemic that heart disease patients are disproportionately affected by the coronavirus and experience higher rates of mortality and morbidity. Further, patients without a history of heart disease have worse prognosis when they develop cardiac complications caused by the virus. By adding COVID-19 data elements to existing registries, ACC and participating clinicians, hospitals and health systems can monitor the impact of COVID-19 on patients experiencing a heart attack or undergoing cardiac catheterization and percutaneous coronary intervention procedures. With the new data module, the registries will collect data on COVID-19 status for all patients in the Chest Pain-MI and CathPCI registries, and among affected patients, also collect key biomarkers that may reflect cardiac damage in COVID-19 patients, hospital events that may reflect complications of COVID-19 and COVID-19 therapies that may have cardiac effects. Long-term data will also allow for future research on COVID-19, including its impacts on specific racial, ethnic and gender groups, and identify where gaps and/or disparities in care exist. The ACC remains committed to helping its members continue to transform cardiovascular care and improve heart health. We are learning every day how COVID-19 impacts our patients. By adapting our registries to answer pressing scientific questions and knowledge gaps, we can ensure that our cardiovascular care team has validated data and updated tools to provide the highest quality care particularly during these uncertain times." Athena Poppas, MD, FACC, ACC President Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More